Global Non-Alcoholic Steatohepatitis (NASH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035
Global Non-Alcoholic
Steatohepatitis (NASH) Market Outlook
Thelansis’s “Global Non-Alcoholic
Steatohepatitis (NASH) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease
overview, epidemiology, kidney biopsy cases, drug utilization, prescription
share analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Non-Alcoholic Steatohepatitis (NASH) treatment modalities options
for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa,
South / Latin America).
Global Non-Alcoholic
Steatohepatitis (NASH) Overview
Metabolic dysfunction-associated
steatohepatitis (MASH), formerly non-alcoholic steatohepatitis (NASH), is a
progressive inflammatory liver disease characterized by hepatic steatosis,
lobular inflammation, hepatocyte ballooning, and progressive fibrosis. Driven
by lipotoxicity, oxidative stress, and metabolic drivers like type 2 diabetes
and obesity, advanced stages pose significant risks of cirrhosis and
hepatocellular carcinoma. Diagnosis combines liver biopsy as the histological
standard with non-invasive elastography and FIB-4 scoring. While sustained
weight reduction remains foundational, the therapeutic paradigm has
fundamentally shifted away from purely lifestyle interventions. Care is
anchored by two major regulatory approvals: the thyroid hormone receptor beta
agonist Rezdiffra (resmetirom) for non-cirrhotic MASH with moderate-to-advanced
fibrosis, and the newly approved GLP-1 receptor agonist Wegovy (semaglutide),
indicated for pre-cirrhotic phenotypes following landmark Phase 3 trials.
Conversely, historical candidates like the farnesoid X receptor agonist
obeticholic acid have been completely abandoned following definitive regulatory
rejections due to safety risks. The active late-stage pipeline relies on
alternative pathways, led by the oral pan-PPAR agonist lanifibranor, which is
completing Phase 3 NATiV3 validation, alongside advanced dual/triple incretins
like tirzepatide. Regular non-invasive tracking is mandatory to guide lifelong
management.
Market
Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech
Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands,
Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United
Kingdom)
- Middle East (Saudi Arabia, UAE,
Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong
Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines,
Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa,
Morocco)
- South / Latin America (Argentina,
Brazil, Chile, Colombia, Mexico, Peru)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across the 32 markets (North
America, Europe, Middle East, Asia Pacific, Africa, South / Latin
America)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment